The scenario
A 22-year-old G0 patient (she/her) comes in for a routine well-person exam. When you ask if she’s ever had a Pap smear, she says she hasn’t. She’s never had penetrative sex and didn’t think she needed one until she did. She says she really doesn’t want one yet because she’s worried it will be painful, and shares that she “doesn’t even use tampons.” She isn’t sure whether she finished the HPV vaccine series as a teenager. She asks you, “Do I really need to do this right now, or is it OK to wait?”
Can nonpenetrative sexual contact transmit HPV?
Yes, although the risk is low. HPV is transmitted through skin-to-skin contact during sex. Penetrative (vaginal or anal) intercourse is the most efficient route, but other types of nonpenetrative sexual contact are associated with increased risk. This includes oral sex, hand-to-genital contact, and genital-to-genital contact with partners of any gender.
Thanks for sharing that with me. Can I ask one more question so I can give you the most accurate answer? (wait for response) HPV, the virus that causes almost all cervical cancer, can spread through any kind of genital contact: hands, mouths, or bodies touching, with a partner of any gender. Have you had any of that kind of contact?
What are the current recommendations for cervical cancer screening for a 22-year old?
USPSTF and HRSA/WPSI recommend starting at 21 with cytology (a Pap test) every 3 years. ACS recommends starting at 25 with HPV-based testing.
| USPSTF(2024 draft) | ACS(2020 guideline, 2025 update) | WPSI(2026) | |
|---|---|---|---|
| Start age | 21 | 25 | 21 |
| Ages 21–24 | Cytology every 3 years | No screening | Cytology every 3 years |
| Ages 25–29 | Cytology every 3 years | Primary HPV every 5 years (preferred); cotesting every 5 years or cytology every 3 years if primary HPV isn’t available | Cytology every 3 years; cotesting not recommended under 30 |
| Ages 30–65 | Primary HPV every 5 years (preferred); cytology every 3 years or cotesting every 5 years as alternatives | Same as ages 25–29 | Primary HPV every 5 years (preferred) or cotesting every 5 years; cytology every 3 years if primary HPV testing isn’t available |
| Self-collection | Ages 30–65, every 5 years | Acceptable at ages 25–65, though clinician collection preferred; repeat every 3 years after a negative self-collected test | Ages 30–65; no separate interval for self-collected samples |
USPSTF: US Preventive Services Task Force · ACS: American Cancer Society · WPSI: Women’s Preventive Services Initiative
The 2024 USPSTF recommendation is still a draft; the 2018 final recommendation remains in effect. For patients ages 21 to 29, both versions recommend cytology every 3 years.
Can a 22-year-old wait until 25 to start cervical cancer screening?
In many cases, yes. Waiting can be a reasonable, guideline-supported choice after counseling. Shared decision making involves a conversation about her sexual history and priorities. In either case, she should leave with a plan for when to revisit screening.
If she’s had no genital contact with another person: her risk is extremely low, and postponing screening is a reasonable choice. Contraceptive Technology advises that people 21 and older who have never had genital sexual contact can be told their risk is extremely low but not zero, and may choose to postpone screening or opt to be screened. Document the conversation and her decision, especially if the patient’s decision departs from the guideline your practice follows.
If she’s had nonpenetrative genital contact: her risk is lower than it would be after vaginal intercourse, but it isn’t zero. USPSTF and WPSI would recommend screening now; ACS would start at 25. Since a national guideline supports waiting until 25, deferring for now is well-supported.
Points to cover in either case:
- Benefits of screening at 22: Screening now could detect a high-grade lesion earlier, but cervical cancer is uncommon at this age. USPSTF notes that the incidence and prevalence of CIN peak between ages 25 and 35.
- Potential harms: Screening can lead to false positives, repeat testing, colposcopy, and biopsy. It can also lead to treatment of lesions that would have resolved on their own.
- Vaccination status: USPSTF modeling found that the lifetime benefit of screening is substantially smaller in vaccinated people, though the Task Force doesn’t yet make recommendations by vaccination status.
- Exam experience: A rushed or painful first pelvic exam can shape how someone approaches screening for years. When the guidelines support waiting, providers can use that time to build trust.
Sample language if she’s had no genital contact:
You don’t have to do this today, and based on what you’ve told me, waiting is a safe choice. Cervical cancer is caused by HPV, which spreads through sexual contact, so your risk right now is very low. Screening is great at finding changes early, but at your age it also finds a lot of changes that would go away on their own, and that can mean extra tests you don’t need. Let’s make a plan instead: we’ll revisit this at your next visit, or sooner if anything changes with your sexual activity. How does that sound?
Sample language if she’s had nonpenetrative contact:
Since you’ve had some sexual contact, the risk of cervical cancer isn’t zero, but it’s very low. Some guidelines recommend starting at 21 and others at 25, so this is your decision to make. If you’d like to wait, we can plan to check in about this again when you turn 25. If you’d rather get it done, we can do it today or at another visit. What questions do you have about those options?
Is HPV self-collection an option for patients under 25?
No. No current guideline supports self-collection before 25. ACS considers self-collected samples acceptable starting at 25, while USPSTF and WPSI recommend starting self-collection at 30. Before 25, screening means cytology, which requires a clinician-collected cervical sample. HPV-based testing isn’t recommended in younger patients because transient HPV infections are so common at this age.
Should a 22-year-old get the HPV vaccine?
Yes. ACIP recommends catch-up HPV vaccination for everyone through age 26 who isn’t fully vaccinated. ACIP doesn’t recommend routine vaccination after age 26, but for adults ages 27 to 45 who aren’t adequately vaccinated, it recommends shared clinical decision-making, since some may benefit if they’re at risk of new HPV exposure. The vaccine is most effective when given before any exposure to HPV, so her limited sexual history means she’s likely to get the full benefit.
If you can, it’s helpful to check records first: your state immunization registry, prior clinics, or family records. If you can’t find documentation and the patient isn’t sure, it’s supported to start the series.
Dosing:
- Starting at 15 or older: 3 doses, with the second and third doses given 1 to 2 months and 6 months after the first.
- Started before 15: 2 doses given at least 6 months apart may already count as a complete series.
- Incomplete series: pick up where she left off. Delays between doses don’t require restarting.
One important note on HPV dosing recommendations: In January 2026, federal officials moved the childhood vaccination schedule to a single HPV dose without going through the usual ACIP approval process; a federal court stayed that change in March 2026 while an appeal proceeds, restoring the prior schedule: 2 doses for patients who start the series at ages 9–14 and 3 doses for those who start at 15 or older. While there is some emerging evidence that a single dose schedule may be non-inferior to two doses in preventing persistent HPV16/18 infection among adolescents, current guidelines still recommend the two-dose schedule.
How can you make a first pelvic exam and cervical cancer screening more comfortable?
Use trauma-informed practices that keep patients in control from start to finish. Her worry about pain is reasonable, and her comment about tampons suggests she may have little experience with vaginal insertion. If she describes pain with attempted insertion, explore that as a separate concern.
Contraceptive Technology recommends approaches that include:
- Offering a separate visit: Talk through the exam today, and offer to perform it at another visit if she’d prefer.
- Asking for consent at each step: Get consent before starting, and confirm it as you go.
- Using the smallest speculum that allows visualization: Offer patient-guided or self-insertion, and moisten the speculum with warm water or a small amount of lubricant applied at the introitus, away from the tip.
- Agreeing on a stop signal in advance: If she says stop, stop.
Key Points
- In shared-decision making conversations about when to begin cervical cancer screening, ask about all forms of genital contact, not only penetrative sex. HPV can spread through any genital contact.
- USPSTF and HRSA/WPSI recommend starting at 21 with cytology every 3 years. ACS recommends starting at 25 with HPV-based testing.
- For patients with no history of penetrative sex, waiting until 25 to revisit the conversation is a reasonable, guideline-supported choice after counseling.
- Self-collection isn’t a guideline support option before age 25. ACS recommendations allow it starting at 25, with repeat testing every 3 years; USPSTF and WPSI guidelines start at 30.
- Recommend HPV catch-up vaccination through age 26, and take a shared decision making approach for people 27-45. Patients starting at 15 or older need 3 doses, but an incomplete series doesn’t need to be restarted.
Clinical Resources
- USPSTF Draft Recommendation: Cervical Cancer Screening (2024)
- American Cancer Society Guideline for Cervical Cancer Screening
- Women’s Preventive Services Initiative: Cervical Cancer Screening
- ACIP Recommendations: HPV Vaccination for Adults (MMWR, 2019)
- Bedsider Providers: Trauma-Informed Care Is Respectful Care
- Contraceptive Technology, 22nd edition: Chapter 24, Screening for Cervical, Ovarian, and Breast Cancer; Chapter 22, Box 22-1, Trauma-Informed Care